Evidence mapPaperPMID 28643299Full record

SynthesisJournal of endocrinological investigation2018

The association between circulating fetuin-A levels and type 2 diabetes mellitus risk: systematic review and meta-analysis of observational studies.

F Roshanzamir, M Miraghajani, M H Rouhani, M Mansourian, R Ghiasvand, S M Safavi

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Journal of endocrinological investigation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 3 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Review
  7. Review
  8. Review
  9. Apigenin targets fetuin-A to ameliorate obesity-induced insulin resistance.International journal of biological sciences · 2024
    Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Observational
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

F RoshanzamirNoncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.
M MiraghajaniCancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
M H RouhaniFood Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
M MansourianDepartment of Biostatistics and Epidemiology, Health School, Isfahan University of Medical Sciences, Isfahan, Iran.
R GhiasvandFood Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
S M SafaviFood Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. safavimorteza@yahoo.com.
Isfahan University of Medical Sciences · IRFasa University of Medical Sciences · IRShahid Beheshti University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveFetuin-A is a liver-derived circulating protein that is associated with insulin resistance and diabetes. The objective of this systematic review and meta-analysis of published observational studies was to investigate mean levels of fetuin-A in T2D patients and the relationship between blood fetuin-A levels and T2D risk. MATERIALS AND

methodsPubMed, Embase, Google Scholar, Web of Science, and The Cochrane Library were systematically searched for potential relevant studies up to 1 December 2016. Natural logarithm-transformed estimate risks, standard mean differences on the basis of Hedges's adjusted g, and 95% confidence intervals (CIs) were calculated for all eligible studies and were combined to measure the pooled data using random-effects model.

resultsA total of 32 studies including 27 case-control and 5 cohort studies were included in the current study. Fetuin-A levels in T2D patients were significantly higher than control groups [Hedges' g = 1.73, 95% CI (1.25-2.22), P < 0.001], with significant heterogeneity across studies (P < 0.001, I

conclusionWe found a significant relationship between the fetuin-A levels with T2D risk. Although fetuin-A may be as a potential screening and prediction biomarker or a therapeutic target in T2D patients, further studies are required in this regard.

Indexed as

alpha-2-HS-GlycoproteinBiomarkersCase-Control StudiesDiabetes Mellitus, Type 2HumansInsulin ResistanceRisk Factorsalpha-2-HS-GlycoproteinBiomarkersFetuin-AMeta-analysisType 2 diabetes

Identifiers

PMID28643299
OpenAlexW2687880466

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.